EAU 2013 - Programme Book - YouMed

Friday, 15 March
Sponsored Session
16.15 - 17.45 Metastatic castration-resistant prostate cancer: Integrating new
learnings to optimise treatment outcomes
Brown Hall 3 - Level S2
Symposium
Chair: J.M. Fitzpatrick, Dublin (IE)
Welcome and introduction
J.M. Fitzpatrick, Dublin (IE)
The evolving mCRPC landscape: Challenges and opportunities
N. Mottet, Saint Etienne (FR)
The androgen signaling pathway in mCRPC: Implications in daily practice
J.M. Fitzpatrick, Dublin (IE)
Tailoring therapy to optimise treatment outcomes in mCRPC
S. Oudard, Paris (FR)
Managing mCRPC in real life practice
A. Bahl, Bristol (GB)
Closing remarks
J.M. Fitzpatrick, Dublin (IE)
Aims and objectives
The objectives of this symposium are (1) to discuss the current and emerging treatment options in metastatic
castration-resistant prostate cancer, (2) to reach a better understanding of the complexity of androgen
receptor signaling pathway and how these new agents interfere with it, and (3) to share views on how to
best sequence or combine available therapies.
Sponsored by SANOFI
EAU Milan 2013
401
Sponsored Sessions